Guangwen Lu

Guangwen Lu

Auto-generated profile, based on publicly available information

Guangwen Lu

Department of Emergency Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JYJingyun Yang
Jingyun Yang
WWWei Wang
Wei Wang
ZCZimin Chen
Zimin Chen
SLShuaiyao Lu
Shuaiyao Lu
FYFanli Yang
Fanli Yang
XWXiawei Wei
Xiawei Wei

13 December 2021 in Medcomm
Verified
Journal Article
Open access
PDF file
XHXuemei He
Xuemei He
WHWeiqi Hong
Weiqi Hong
XPXiangyu Pan
Xiangyu Pan
GLGuangwen Lu
Guangwen Lu
XWXiawei Wei
Xiawei Wei
Coronavirus disease 2019 (COVID‐19) has brought about a great threat to global public health. Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variant B.1.1.529 has been reported in South Africa and induced a rapid increase in COVID‐19 cases. On November 24, 2021, B.1.1.529 named Omicron was designated as a variant under monitoring (VUM) by World Health Organization (WHO). Two days later, the Omicron variant was classified as a variant of concern (VOC). This variant harbors a high number of mutations, including 15 mutations in the receptor‐binding domain (RBD) of spike. The Omicron variant also shares several mutations with the previous VOC Alpha, Beta, and Gamma variants, which immediately raised global concerns about viral transmissibility, pathogenicity, and immune evasion. Here we described the discovery and characteristics of the Omicron variant, compared the mutations of the spike in the five VOCs, and further raised possible strategies to prevent and overcome the prevalence of the Omicron variant.

26 March 2021 in Science
Verified
Journal Article
Open access
PDF file
JQJingxin Qiao
Jingxin Qiao
YLYue-Shan Li
Yue-Shan Li
RZRui Zeng
Rui Zeng
FLFeng-Liang Liu
Feng-Liang Liu
RLRong-Hua Luo
Rong-Hua Luo
SYShengyong Yang
Shengyong Yang
Targeting the SARS-CoV-2 main protease: Vaccines are an important tool in the fight against COVID-19, but developing antiviral drugs is also a high priority, especially with the rise of variants that may partially evade vaccines. The viral protein main protease is required for cleaving precursor polyproteins into functional viral proteins. This essential function makes it a key drug target. Qiao et al. designed 32 inhibitors based on either boceprevir or telaprevir, both of which are protease inhibitors approved to treat hepatitis C virus. Six compounds protected cells from viral infection with high potency, and two of these were selected for in vivo studies based on pharmokinetic experiments. Both showed strong antiviral activity in a mouse model. Science , this issue p. 1374

5 March 2024 in Nature Methods
Verified
Journal Article
Open access
PDF file
MZMing Zhang
Ming Zhang
CTChao Tang
Chao Tang
ZWZichun Wang
Zichun Wang
SCShanchuan Chen
Shanchuan Chen
DZDan Zhang
Dan Zhang
JGJia Geng
Jia Geng
Precise identification and quantification of amino acids is crucial for many biological applications. Here we report a copper(II)-functionalized Mycobacterium smegmatis porin A (MspA) nanopore with the N91H substitution, which enables direct identification of all 20 proteinogenic amino acids when combined with a machine-learning algorithm. The validation accuracy reaches 99.1%, with 30.9% signal recovery. The feasibility of ultrasensitive quantification of amino acids was also demonstrated at the nanomolar range. Furthermore, the capability of this system for real-time analyses of two representative post-translational modifications (PTMs), one unnatural amino acid and ten synthetic peptides using exopeptidases, including clinically relevant peptides associated with Alzheimer’s disease and cancer neoantigens, was demonstrated. Notably, our strategy successfully distinguishes peptides with only one amino acid difference from the hydrolysate and provides the possibility to infer the peptide sequence.

6 May 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SLSheng Lin
Sheng Lin
HCHua Chen
Hua Chen
ZCZimin Chen
Zimin Chen
FYFanli Yang
Fanli Yang
FYFei Ye
Fei Ye
GLGuangwen Lu
Guangwen Lu
The emergence of SARS-CoV-2 infection has posed unprecedented threat to global public health. The virus-encoded non-structural protein 14 (nsp14) is a bi-functional enzyme consisting of an exoribonuclease (ExoN) domain and a methyltransferase (MTase) domain and plays a pivotal role in viral replication. Here, we report the structure of SARS-CoV-2 nsp14-ExoN domain bound to its co-factor nsp10 and show that, compared to the SARS-CoV nsp10/nsp14-full-length complex, SARS-CoV-2 nsp14-ExoN retains an integral exoribonuclease fold and preserves an active configuration in the catalytic center. Analysis of the nsp10/nsp14-ExoN interface reveals a footprint in nsp10 extensively overlapping with that observed in the nsp10/nsp16 structure. A marked difference in the co-factor when engaging nsp14 and nsp16 lies in helix-α1′, which is further experimentally ascertained to be involved in nsp14-binding but not in nsp16-engagement. Finally, we also show that nsp10/nsp14-ExoN is enzymatically active despite the absence of nsp14-MTase domain. These data demonstrate that SARS-CoV-2 nsp10/nsp14-ExoN functions as an exoribonuclease with both structural and functional integrity.

1 March 2020 in Cell Host & Microbe
Verified
Journal Article
Closed access
FYFanli Yang
Fanli Yang
SLSheng Lin
Sheng Lin
FYFei Ye
Fei Ye
JYJing Yang
Jing Yang
JQJianxun Qi
Jianxun Qi
GLGuangwen Lu
Guangwen Lu